ClinicalTrials.gg
WithdrawnNCT05481489PRO-230Updated Jul 1, 2024

Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution

A Phase 1 interventional study of Atropine Sulfate in Myopia, sponsored by Laboratorios Sophia S.A de C.V.. Withdrawn. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Laboratorios Sophia S.A de C.V. · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Due to sponsors convenience.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Enrollment
54th of 54
0 · median 144
Started
2023
with 7 others
Phase 1
8 of 54
none open now
Registered
29th of 54
by date
Lead sponsor
2 of 54
Laboratorios Sophia S.A de C.V.

Among the 54 studies testing atropine in Myopia, this one is the 54th largest by enrollment, is one of 8 that started in 2023, is one of 8 in phase 1, and was the 29th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

Phase I Study to evaluate safety and tolerability of PRO-230 (atropine sulphate 0.05%) ophthalmic solution through evaluation of incidence of non-expected adverse events (AE), photophobia, pupillary diameter, incidence of expected adverse events, and best near corrected visual acuity (BNCVA)

Read the detailed description

A total of 29 healthy volunteers will apply PRO-230 ocular solution on both eyes QD (one time per day) for 14 days. The safety variables will include non expected AE, pupillary diameter and expected AE; tolerability variables will include incidence of photofobia, and BNCVA. Exploratory variables include best corrected visual acuity (BCVA), intraocular pressure (IOP), corneal an conjunctival staining with fluorescein and lissamine green, vital signs (heart rate and blood pressure), and results of the Ocular Confort Index (OCI) questionnaire.

The presence of non-expected AE \< 10% will deem PRO-230 as safe; while an incidence of photophobia \< 30% will deem PRO-230 as tolerable.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being clinically healthy
  • Ability to voluntarily sign an form (ICF).
  • Ability and willingness to comply with the scheduled visits according to the intervention plan and other procedures of the study.
  • Age between 18 and 35.
  • Absence of history of contact lens use.
  • Women of childbearing age must agree to continue (starting ≥ 30 days previous to the ICF) the use of a hormonal method of a intrauterine device (IUD) during the period of the study.
  • Best corrected visual acuity (BVCA) of at least 20/30 (logMAR 0.2) or better in both eyes.
  • Best near corrected visual acuity (BNVCA) of at least 20/25 (logMAR 0.1) or better in both eyes.
  • Presenting vital signs within normal parameters.
  • Presenting an IOP ≥10 and ≤ 21 mmHg

Exclusion criteria

Exclusion Criteria:

  • Using any kind of ophthalmic topical products.
  • Presenting known allergy or intolerance to any ingrediente of atropine eyedrops or any other derivatives of antimuscarinic agents.
  • Using any medication of herbolary products (plant extracts, infusions, naturist preparations, homeopathy, etc) through any route of administration
  • For women: being pregnant, breastfeeding or planning to get pregnant during the period of the study.
  • Having participated in any clinical study 90 days prior to the inclusion in this study.
  • Having participated in this clinical study.
  • History of any chronic degenerative disease, including diabetes and hypertension.
  • Presenting active inflammatory or infectious diseases when entering this study.
  • Presenting unresolved lesions or trauma when entering this study.
  • History of any ocular surgery.
  • History of any surgery, non-ocular, within the previous 3 months of entering this studies.
  • Being or having an direct family member (spouse, parent/legal guardian, sibling, etc) as employee of the investigation site or the sponsor, who participates directly in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    PRO-230

    Healthy volunteers will apply one drop of PRO-230 ophthalmic solution (atropine sulphate) on both eyes, QD (one time per day) for 14 days.

    Drug: Atropine Sulfate

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of unexpected adverse events

    The number of adverse events presented that are not previously described / known for the active substance in this pharmaceutic form and concentration.

    Time frame: Through Day 21 ± 1 (Safety Call)

  2. Incidence of photophobia

    The number of cases of photophobia.

    Time frame: Through Day 21 ± 1 (Safety Call)

Secondary outcomes

  1. Pupillary Diameter

    Change of pupillary diameter after exposure to the investigation product.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)]

  2. Incidence of expected adverse events

    The number of adverse events presented that are previously described / known for the active substance in this pharmaceutic form and concentration.

    Time frame: Through Day 21 ± 1 (Safety Call)

  3. Measurement of the change in best near corrected visual acuity (BNCVA)

    The change in BNCVA after exposure to investigation product, compared to basal value.

    Time frame: Time Frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

Other outcomes

  1. Measurement of the change in best corrected visual acuity (BCVA)

    The change in BCVA after exposure to investigation product, compared to basal value.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

  2. Changes in intraocular pressure (IOP)

    The change in IOP after exposure to investigation product, compared to basal value.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

  3. Incidence of corneal and conjunctival staining

    Presence of corneal and conjunctival staining with fluorescein and lissamine green after exposure to investigation product.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)]

  4. Measurement of vital signs (blood pressure)

    The change in blood pressure after exposure to investigation product, compared to basal value.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

  5. Measurement of vital signs (heart rate)

    The change in heart rate after exposure to investigation product, compared to basal value.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

  6. Value of the ocular comfort index (OCI) questionnaire

    The change ocular comfort index (OCI) questionnaire results after exposure to investigation product, compared to basal value.

    Time frame: Days: 1 (Basal Visit), 16 ± 1 (Final Visit)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2023; primary completion for Mar 2023, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2022
First posted
Aug 1, 2022
StartEst.
Feb 1, 2023
Primary completionEst.
Mar 31, 2023
CompletionActual
Apr 24, 2023
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05481489
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Feb 1, 2023 (estimated)
Primary completion
Mar 31, 2023 (estimated)
Completion
Apr 24, 2023
Last update
Jul 1, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion